Regulatory ProfessionalsRegulatory ProfessionalsRegulatory ProfessionalsRegulatory Professionals
  • About Us
    • Our Story
    • Leadership
    • Senior Consultants
  • Services
    • Overview
    • Regulatory Affairs Strategy
    • Electronic Publishing | eCTD
    • Medical and Regulatory Writing
    • Quality Assurance
    • Project Management
    • Electronic Trial Master File | eTMF
  • Resources
    • Blog
    • White Papers
    • News
  • Careers
  • Contact

COVID-19 Update: How the FDA’s Emergency Use Authorization Can Help Develop Therapies Faster

    Home Blog COVID-19 Update: How the FDA’s Emergency Use Authorization Can Help Develop Therapies Faster
    NextPrevious

    COVID-19 Update: How the FDA’s Emergency Use Authorization Can Help Develop Therapies Faster

    By Nach Davé | Blog, COVID-19, Podcast | Comments are Closed | 8 April, 2020 | 0

    As we continue to face the ongoing COVID-19 health emergency, the medical community is tasked with bringing solutions to patients in an expedited and safe manner. One such opportunity is to partner with the US FDA by submitting an Emergency Use Authorization (EUA) for any products that could immediately and effectively address a health emergency.

    In this episode, Nach Dave, Premier Research’s Vice President of Development Strategy, discusses key considerations for sponsors interested in applying for an EUA, including:

    • How it allows the FDA to help strengthen the nation’s public health options
    • How to know if your product is a good fit
    • Actionable steps you can take toward seeking an EUA

    Read Nach’s blog at https://premier-research.com/what-is-fda-emergency-use-authorization-eua/.

    Find more resources at premier-research.com/covid-19/.

    Contact our COVID-19 Task Force at COVID-19_taskforce@premier-research.com.

     

    No tags.
    Avatar

    Nach Davé

    More posts by Nach Davé

    Related Post

    • RPI Acquired by Premier Research to Expand Regulatory Offerings

      By Regulatory Professionals | Comments are Closed

      NEWARK, Calif., JULY 30, 2018 — Regulatory Professionals, Inc., has joined Premier Research, a global provider of clinical development services, in a partnership that will offer regulatory solutions to biotechnology, pharmaceutical, and medical device companies.Read more

    • Regulatory CMC for Biologics / Biopharmaceuticals

      By Regulatory Professionals | Comments are Closed

      Learn about Master Cell Bank concerns and other areas of concern. Download the white paper here.Read more

    • Streamline Early Clinical Development With an INTERACT Meeting

      By Ann Leonard | Comments are Closed

      In October 2018, the Food and Drug Administration (FDA) issued Standard Operating Policy and Procedure (SOPP) – SOPP 8214 Version 1.0: INTERACT Meetings with Sponsors for Drugs and Biological Products. This document details recommendations forRead more

    • FDA Releases Draft Guidance for Transdermal Product Development

      By Lisa Crose | Comments are Closed

      Transdermal and topical delivery systems (TDS) are important dosage forms that allow delivery of a drug to local tissue or provide systemic delivery through the skin. These drug products provide a number of advantages forRead more

    • UPDATE – Draft FDA Guidance Concerning Combination Products

      By Ann Leonard | Comments are Closed

      As those working in the development of combination products likely know, the Food and Drug Administration (FDA) issued two new draft guidances in December 2019. The guidances – Requesting FDA Feedback on Combination Products andRead more

    • FDA Issues Guidance on Clinical Trials During COVID-19

      By Nach Davé | Comments are Closed

      Earlier this week, the FDA issued a guidance on the conduct of clinical trials during the ongoing Coronavirus Disease 2019 (COVID-19) pandemic. “The FDA released this guidance to emphasize that at all times, patients’ safetyRead more

    • Global Health Authorities Push for Rapid Development of COVID-19 Tests, Drugs and Vaccines

      By Katharine Chorlton | Comments are Closed

      In response to the Coronavirus Disease 19 (COVID-19) pandemic, the scientific community, industry, and regulatory agencies are pulling together to facilitate the development of diagnostic tests, drugs, and vaccines to help prevent the spread ofRead more

    • What Is FDA’s Emergency Use Authorization (EUA) and How Can It Help Develop Therapies Faster?

      By Nach Davé | Comments are Closed

      As we continue to face health emergencies and imminent threats to our safety and well-being, the medical community is tasked with bringing solutions to the patients in an expedited and safe manner. One such opportunityRead more

    NextPrevious

    Recent Posts

    • Beware of Underestimating the Value of a Pre-NDA Meeting
    • Outsourcing-Pharma.com: Holistic Approach Benefits Drug Development
    • 5 Tips to Avoid an IND Clinical Hold: Regulatory Guidance and Insights
    • The FDA Is Ending Its Rare Pediatric Disease Priority Review Vouchers – and Time Is Running Out to Get One
    • Creating a Compliant eCTD: Avoiding Common Regulatory and Technical Pitfalls on the Path to Submission

    Categories

    • Blog
    • CMC
    • COVID-19
    • FDA
    • INTERACT Meeting
    • News
    • Podcast
    • Regulatory Affairs
    • White Papers
    January 2021
    M T W T F S S
    « Nov    
     123
    45678910
    11121314151617
    18192021222324
    25262728293031

    Headquarters

    8000 Jarvis Ave.
    Suite 100
    Newark, CA 94560

    North Carolina

    One Park Drive, Suite 150
    Box 13608
    Research Triangle Park,
    NC 27709

    San Diego

    Aventine Building
    8910 University Center Lane
    Suite 400 San Diego, CA 92122

    United Kingdom

    250 South Oak Way
    Green Park
    Reading, Berkshire, RG2 6UG

    Australia

    Premier Research Australia Pty Ltd.
    Ground Floor, 23 Milton Parade
    Malvern VIC 3144

    • Home
    • About Us
    • Services
    • Cookie Policy
    • Privacy Notice
    • Contact
    Copyright 2020 Regulatory Professionals | All Rights Reserved
    • About Us
      • Our Story
      • Leadership
      • Senior Consultants
    • Services
      • Overview
      • Regulatory Affairs Strategy
      • Electronic Publishing | eCTD
      • Medical and Regulatory Writing
      • Quality Assurance
      • Project Management
      • Electronic Trial Master File | eTMF
    • Resources
      • Blog
      • White Papers
      • News
    • Careers
    • Contact
    Regulatory Professionals
    XWe use cookies (and equivalent technologies) to collect and analyze information on our Website’s performance and to enable the Website to function. Cookies also allow us and third parties to tailor the ads you see when you visit our Website and other third party websites in the same online network, including social networks. By clicking ‘AGREE', you agree to these uses of cookies. If you do not agree or if you would like more information, you can manage your cookie preferences by clicking on 'Cookie Settings'. Cookie Policy REJECTAGREECookie Settings
    Privacy & Cookies Policy

    Privacy Overview

    This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
    Necessary
    Always Enabled

    Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.

    Non Necessary

    Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.

    Save & Accept